impact factor, citescore
logo
 

Rapid paper

 

Anakinra desensitisation in patients with cryopyrin-associated periodic syndromes


1, 2, 3, 4

 

  1. Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, and Department of Immunology, SA Pathology, Adelaide, Australia. syed.ali@sa.gov.au
  2. Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, Australia.
  3. Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, Australia.
  4. Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, and Department of Immunology, SA Pathology, Adelaide, Australia.

CER14204
2021 Vol.39, N°1
PI 0013, PF 0016
Rapid paper

Free to view
(click on article PDF icon to read the article)

PMID: 33427612 [PubMed]

Received: 07/11/2020
Accepted : 14/12/2020
In Press: 11/01/2021
Published: 05/02/2021

Abstract

Cryopyrin-associated periodic syndrome (CAPS) is rare and patients experience rashes, arthralgias and fevers despite supportive treatment. In these cases, anakinra subcutaneous therapy is indicated which provides symptom control. However, adverse reactions notably injection-site related, are common resulting in treatment cessation in these patients. Ongoing symptoms lead to morbidity and predispose patients to complications such as amyloidosis. We describe our experience with anakinra desensitisation in two cases with CAPS who had injection-site related reactions. We also propose a 34-day outpatient desensitisation protocol.

DOI: https://doi.org/10.55563/clinexprheumatol/gskapp

Rheumatology Article